天境生物上涨11.01%，报5.728美元/股，总市值6.59亿美元

Core Insights - Tianjing Bio (IMAB) experienced a stock price increase of 11.01% on August 15, reaching $5.728 per share, with a trading volume of $5.7998 million and a total market capitalization of $659 million [1] Financial Performance - As of December 31, 2023, Tianjing Bio reported total revenue of 27.644 million RMB, representing a year-on-year growth of 112.48% [1] - The company recorded a net profit attributable to shareholders of -1.466 billion RMB, which is a year-on-year increase of 41.54% [1] Upcoming Events - Tianjing Bio is scheduled to disclose its fiscal year 2024 mid-term report on August 28, with the data sourced from NASDAQ, and the actual disclosure date will be confirmed by the company's announcement [1] Company Overview - Tianjing Bio is an offshore holding company registered abroad, operating through its domestic subsidiary Tianjing Bio [1] - The company focuses on innovative biopharmaceuticals in the fields of tumor immunology and autoimmune diseases, aiming to develop "first-in-class" and "best-in-class" innovative drugs globally [1] - The mission of the company is to create groundbreaking innovative biopharmaceuticals that address unmet clinical needs and significantly improve the quality of life for patients worldwide, striving to become a leading biopharmaceutical company rooted in China and oriented towards global markets [1]